Claudia Jessica Castillo Villanueva

Dr. Claudia Jessica Castillo Villanueva


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
CVClaudia Jessica Castillo Villanueva
Claudia Jessica Castillo Villanueva
JAJhony Anacleto-Santos
Jhony Anacleto-Santos
TLTeresa de Jesús López-Pérez
Teresa de Jesús López-Pérez
BCBrenda Casarrubias-Tabarez
Brenda Casarrubias-Tabarez
TFTeresa I. Fortoul
Teresa I. Fortoul
NRNorma Rivera
Norma Rivera
Toxoplasma gondii is an obligate intracellular parasite of the phylum Apicomplexa and the causative agent of toxoplasmosis, a disease with a worldwide distribution that causes serious consequences in immunocompromised patients and during pregnancy. Current pharmacological treatments have significant limitations, including their toxicity, lack of efficacy against the chronic phase of the parasite, and low selectivity, highlighting the need to develop new therapeutic targets. One of the most promising targets is the fatty acid synthesis pathway II (FASII), a metabolic pathway located in the parasite’s apicoplast and absent in mammalian hosts. This review synthesizes the available evidence on FASII pathway inhibitors described to date, as well as their potential impact on the viability and development of T. gondii. Overall, the reviewed studies support the FASII pathway as an attractive therapeutic target for the development of more selective and effective treatments against toxoplasmosis.